Treatment of central nervous system disorders

US8940902B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• R. Scott Bitner · Pleasant Prairie, US
• Kaitlin E. Browman · Deerfield, US
• Michael E. Brune · Mundelein, US
• Yixian Chen · Park City, US
• Jurgen Dinges · Wadsworth, US
• Karla Drescher · Ludwigshafen, DE
• Peer B. Jacobson · Libertyville, US
• Hwan-Soo Jae · Glencoe, US
• Ravi Kurukulasuriya · Gurnee, US
• James T. Link · Stanford, US
• David J. Madar · Gilbert, US
• Jyoti R. Patel · Libertyville, US
• Marina Pliushchev · Vernon Hills, US
• Jeffrey J. Rohde · Evanston, US
• Lynne E. Rueter · Round Lake Beach, US
• Qi Shuai · DeKalb, US
• Bryan K. Sorensen · Antioch, US
• Jiahong Wang · Northbrook, US
• Karsten Wicke · Ludwigshafen, DE
• Martin Winn · Deerfield, US
• Dariusz Wodka · Waukegan, US
• Vince Yeh · San Diego, US
• Hong Yong · Libertyville, US

Key dates

• Filing date: Jul 20, 2012
• Grant date: Jan 27, 2015
• Expiry date: Jul 20, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.